Clinical Trials Logo

Neoplasms, Plasma Cell clinical trials

View clinical trials related to Neoplasms, Plasma Cell.

Filter by:

NCT ID: NCT05497102 Recruiting - Multiple Myeloma Clinical Trials

Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT

KMM1911
Start date: November 8, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of salvage treatment with carfilzomib/lenalidomide/dexamethasone (KRD) followed by 2nd autologous stem cell transplantation (ASCT) and lenalidomide maintenance in patients with relapsed myeloma after 1st ASCT.

NCT ID: NCT05486975 Recruiting - Clinical trials for Relapsed and/or Refractory Multiple Myeloma

This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.

Start date: August 10, 2022
Phase: Early Phase 1
Study type: Interventional

This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0591CP in patients with relapsed and/or refractory multiple myeloma.

NCT ID: NCT05478993 Recruiting - Multiple Myeloma Clinical Trials

Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement

SPODUMENE
Start date: October 12, 2022
Phase: Phase 2
Study type: Interventional

This is a single-arm, open-label, multicenter, exploratory study initiated by investigator to evaluate the efficacy and safety of Selinexor (S) combined with pomalidomide (P) and dexamethasone (D) in the treatment of multiple myeloma with CNS involvement.

NCT ID: NCT05478343 Recruiting - Multiple Myeloma Clinical Trials

Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma

Start date: May 6, 2021
Phase: Early Phase 1
Study type: Interventional

This is a open-label to determine the efficacy and safety of IM21 CAR-T cells in adult with R/R multiple myeloma.

NCT ID: NCT05477797 Recruiting - Overall Survival Clinical Trials

Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.

Start date: February 16, 2023
Phase: N/A
Study type: Interventional

Newly Diagnosed Myeloma Patients, who achieved efficacy above VGPR (very good PR)after initial treatment were enrolled. Patients were then randomly assigned to Id and Rd groups for maintenance treatment. Therapeutic effectiveness will be reviewed monthly until intolerant side effect or disease progression appear . The follow-up period is approximately 2 years.

NCT ID: NCT05469893 Recruiting - Multiple Myeloma Clinical Trials

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Start date: August 10, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually do not have symptoms but are at risk for progressing to active multiple myeloma (MM). Multiple Myeloma is a cancer of the plasma cells, which are an important part of the immune system. Patients with active multiple myeloma generally require treatment but there are currently no approved therapies for smoldering multiple myeloma. The names of the study drugs involved in this study are: - Teclistamab - Lenalidomide (also called Revlimid) - Dexamethasone (also called Decadron)

NCT ID: NCT05455320 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

MonumenTAL-3
Start date: October 13, 2022
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).

NCT ID: NCT05448404 Recruiting - Multiple Myeloma Clinical Trials

A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma

Start date: March 8, 2022
Phase: N/A
Study type: Interventional

Multiple myeloma (MM) is the second most common hematological malignancy and is still incurable. Positron emission tomography/computed tomography (PET/CT) has been used to diagnose, assess treatment response, and predict prognosis in MM. 18F-fluorodeoxyglucose (FDG) is the most widely used radiotracer, but there is heterogeneous uptake in MM, that is, uptake is negative in some myeloma cells. There are currently reports of cases with strong uptake of prostate-specific membrane antigen (PSMA) PET/CT in MM. Therefore, this preliminary study was designed to compare the imaging results of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT, and to evaluate the additional value of 18F-PSMA-1007 PET/CT to 18F-FDG PET/CT in MM.

NCT ID: NCT05442580 Recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

CART-38 in Adult AML and MM Patients

Start date: May 30, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label Phase 1 study to estimate the safety and manufacturing feasibility of lentivirally transduced T cells expressing anti-CD38 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains in patients with Acute Myeloid Leukemia and Multiple Myeloma. This CAR T cell product will be referred to as "CART-38 cells".

NCT ID: NCT05438394 Recruiting - Multiple Myeloma Clinical Trials

Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM

Start date: October 13, 2022
Phase: Phase 1
Study type: Interventional

This study is an investigator-initiated clinical study to evaluate the safety and tolerability of melphalan hydrochloride for injection in patients with relapsed or relapsed refractory multiple myeloma. Using the "3 + 3" dose escalation principle, 3-6 subjects per dose were enrolled, depending on the dose limiting toxicity (DLT) observed in the first cycle of chemotherapy for each subject. After completing the 21-day assessment of the first cycle of chemotherapy, if there was no DLT, the study started for the next dose group.